Med Cell International / Med Cell Bahamas

The main objective of Med Cell Bahamas is to establish a worldwide “centre of excellence” in stem cell medicine (translational and regenerative medicine) with adipose-derived (fat tissue) adult stem cells in The Bahamas.

To achieve this goal, it is establishing a stem cell medical centre for current and future uses of mesenchymal stem cells and their secretome, a GMP-conform state-of-the-art manufacturing laboratory and cell banking facility, a GLP-conform research laboratory, international and national connections to researchers and clinicians.

It is fully licensed and approved be the Ministry of Health, the National Stem Cell Ethics Committee (NSCEC) and the Bahamas Investment Authorities (BIA) to conduct research & therapies with adipose-derived, adult, autologous (own) stem cells as well as stem cell banking (cryopreservation).

Med Cell so far will be the only facility to offer a GMP-conform laboratory for the processing of stem cells and their cryopreservation in the Bahamas and is therefore ideally positioned to take advantage of the exponentially rising demand for cell treatments.

In the 21st Century, live expectancy has rapidly progressed as has the number of previously uncommon diseases with no treatment. Stem Cell based therapies are able to repair and regenerate cells and tissues in diseases such as autoimmune diseases, osteoarthritis, cardiovascular hypoxia, skin and neurological diseases and stroke.

We are able to adapt treatments with the secretome of mesenchymal stem cells to different diseases as well as to individual patients.

Our ExoRAP® and ExoPAN® technology uses a protocol of pre-treatment of the cultured MSC in special media and various anoxia conditions instead of hypoxia. With this protocol a 30 fold increase in RNA content per cell can be achieved. Our knowhow is based on the right (proven & tested & validated) amount and type of media used and the perfect cultivation and production conditions.

We can alter the secretome according to the disease condition of the patient enabling disease-focused individual treatments.

Additional objectives are:

  • Encourage and perform research into all aspects of translational and regenerative medicine
  • Attract funding into above research and funding for treatments with regenerative and translational medicine
  • Conduct and or monitor clinical trials with mesenchymal stem cells
  • Establish Bahamas as place with excellent stem cell reputation regarding safety and efficacy

Med Cell will offer a “full-service-package” to international new and existing clients thereby maximizing value and income generation and creating a high “entry barrier” for competitors.

The company is offering its services and products based on the know-how, IP and patents generated by the Swiss operations since 2010 with a proven and successful track record (proof of concept).

The Company continues investing into researching and treating a variety of diseases with mesenchymal stem cells and their secretome. One focus will be on Neurodegenerative diseases, the largest medical, social and socio-economical challenge of our time. Preclinical and clinical trials for Alzheimer Disease, Dementia and Parkinson Disease are being prepared and registration as ATMP (advanced therapy medicinal product) as well as autologous treatments is envisaged.

The Bahamas is an ideal location for clients from our main target market North America and knows no income or capital gain taxes. Our target markets and existing client base are VIPs, high-wealth business people and individuals as well as athletes from around the world and specifically North America.

The Company has a solid R&D pipeline for stem cell production and treatments and is in a position to expand the range of treatments currently offered to more illnesses e.g. neurological diseases and Diabetes, in a very short period of time.

Visit Website: www.medcellbahamas.com